

# A Biospecimen Collection Study of Leukapheresis-Derived Circulating Tumor Cells, Immune Cells, and Progenitor Cells.

NCT00571389

---

**Status** RECRUITING  
**Sponsor** BioCytics, Inc.  
**Enrollment** 1,500 participants

## Key Eligibility Criteria

---

### Inclusion (32)

- Male or Female Adult e 18 years of age.
  - Histological diagnosis of any solid tumor type and at any stage of disease progression including in the neoadjuvant/presurgical setting, adjuvant setting, or considered in remission.
  - Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 3 (see Appendix 2) and an estimated life expectancy of at least 3 months.
  - Subject or subject's legal representative provides written informed consent.
  - Negative serology screening test for HIV, Hepatitis B surface antigen, and Hepatitis C antibody, or negative reflex PCR test result for HIV, Hepatitis B Virus (HBV), and Hepatitis C Virus (HCV)
- ... and 27 more (see full listing online)

### Exclusion (4)

- Subjects with active infection requiring therapy (fever, localizing source) will be excluded until the infection resolves.
- a. This excludes subjects with suspected or confirmed COVID-19 by laboratory test while in the acute and sub-acute phase of viremia.
- Underlying medical condition that, in the Principal Investigator's or treating oncologist's opinion, will obscure the interpretation of the patient's safety.
- Confirmed positive reflex PCR test result for HIV, Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV).

## Locations (1 total)

---

Carolina BioOncology Institute, Huntersville, North Carolina, United States